UA99265C2 - Способ получения 1,2,4-оксадиазолбензойной кислоты и ее производных (варианты) - Google Patents

Способ получения 1,2,4-оксадиазолбензойной кислоты и ее производных (варианты)

Info

Publication number
UA99265C2
UA99265C2 UAA200903350A UAA200903350A UA99265C2 UA 99265 C2 UA99265 C2 UA 99265C2 UA A200903350 A UAA200903350 A UA A200903350A UA A200903350 A UAA200903350 A UA A200903350A UA 99265 C2 UA99265 C2 UA 99265C2
Authority
UA
Ukraine
Prior art keywords
processes
preparation
benzoic acid
derivatives
oxadiazole benzoic
Prior art date
Application number
UAA200903350A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Нил Г. АЛЬМСТЕД
Питер Сеонгвоо Хванг
Симон ПАЙНЗ
Йоунг-Чоон Моон
Джеймс Дж. ТАКАСУГИ
Original Assignee
ПиТиСи ТЕРАПЬЮТИКС, ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ПиТиСи ТЕРАПЬЮТИКС, ИНК. filed Critical ПиТиСи ТЕРАПЬЮТИКС, ИНК.
Publication of UA99265C2 publication Critical patent/UA99265C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
UAA200903350A 2006-09-08 2007-09-06 Способ получения 1,2,4-оксадиазолбензойной кислоты и ее производных (варианты) UA99265C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US84359506P 2006-09-08 2006-09-08

Publications (1)

Publication Number Publication Date
UA99265C2 true UA99265C2 (ru) 2012-08-10

Family

ID=38935880

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200903350A UA99265C2 (ru) 2006-09-08 2007-09-06 Способ получения 1,2,4-оксадиазолбензойной кислоты и ее производных (варианты)

Country Status (24)

Country Link
US (2) US7678922B2 (enExample)
EP (1) EP2059513B1 (enExample)
JP (2) JP5955494B2 (enExample)
KR (1) KR101466368B1 (enExample)
CN (1) CN101535284B (enExample)
AR (3) AR062715A1 (enExample)
AU (1) AU2007292915B2 (enExample)
BR (1) BRPI0716996B8 (enExample)
CA (2) CA2662749C (enExample)
CL (1) CL2007002606A1 (enExample)
DK (1) DK2059513T3 (enExample)
ES (1) ES2404348T3 (enExample)
IL (1) IL197445A (enExample)
MX (1) MX2009002439A (enExample)
MY (1) MY148598A (enExample)
NZ (2) NZ598012A (enExample)
PE (2) PE20080771A1 (enExample)
PL (1) PL2059513T3 (enExample)
PT (1) PT2059513E (enExample)
RU (1) RU2495030C2 (enExample)
TW (1) TWI482761B (enExample)
UA (1) UA99265C2 (enExample)
WO (1) WO2008030570A1 (enExample)
ZA (1) ZA200901782B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3889142B1 (en) * 2003-04-11 2022-06-15 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
CA2603402C (en) 2005-04-08 2017-10-31 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
IN2014CN04406A (enExample) * 2006-03-30 2015-09-04 Ptc Therapeutics Inc
MX2009002439A (es) * 2006-09-08 2009-03-27 Ptc Therapeutics Inc Procesos para la preparacion de acidos 1,2,4-oxadiazolbenzoicos.
SG185979A1 (en) 2006-09-25 2012-12-28 Ptc Therapeutics Inc Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
EP2068871B1 (en) 2006-09-25 2013-12-25 PTC Therapeutics, Inc. Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, compositions thereof and the use for nonsense suppression
DK2073805T3 (da) 2006-10-12 2015-06-15 Ptc Therapeutics Inc Fremgangsmåder til dosering af en oralt aktiv 1,2,4-oxadiazol til terapi for suppression af nonsens-mutation
CN101714009A (zh) * 2009-05-14 2010-05-26 翁印嵩 集成通用电话功能的计算机
WO2012101292A1 (es) 2011-01-25 2012-08-02 Viviabiotech, S.L. Derivados de 1,2,4-oxadiazol como fármacos moduladores del receptor para el péptido glp-1
CA2876215A1 (en) 2012-07-02 2014-01-09 Monsanto Technology Llc Processes for the preparation of 3,5-disubstituted-1,2,4-oxadiazoles
CN106455571A (zh) * 2014-03-06 2017-02-22 Ptc医疗公司 1,2,4‑噁二唑苯甲酸的药物组合物和盐
CN105461650B (zh) * 2014-09-12 2018-04-13 杭州普晒医药科技有限公司 一种噁二唑化合物的溶剂化物及其制备方法
CN106316885B (zh) * 2015-07-03 2019-02-12 普济生物科技(台州)有限公司 一种3-[5-(2-氟苯基)-1,2,4-噁二唑-3-基]苯甲酸的制备方法
TW201729807A (zh) 2015-10-30 2017-09-01 Ptc治療公司 用於治療癲癇的方法
TW201808922A (zh) 2016-06-20 2018-03-16 台灣神隆股份有限公司 製備阿塔魯仁及其中間體的方法
US12268669B2 (en) 2018-12-20 2025-04-08 Pfizer Inc. Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent
EA202192767A1 (ru) 2019-04-10 2021-12-29 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Способ лечения опосредуемой нонсенс-мутацией мышечной дистрофии дюшенна у педиатрических пациентов
WO2022112919A1 (en) 2020-11-25 2022-06-02 Pfizer Inc. (aza)benzothiazolyl substituted pyrazole compounds
CN113045510B (zh) * 2021-03-31 2022-05-27 北京大学生命科学华东产业研究院 一种阿塔鲁伦的制备方法
CN114920667B (zh) * 2022-06-30 2024-06-21 湖南大学 一种阿塔鲁伦酯的电化学制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2801509A1 (de) * 1978-01-12 1979-07-19 Schering Ag 1,2,4-oxadiazolderivate, verfahren zur herstellung dieser verbindungen sowie diese enthaltende selektive herbizide mittel
DE3905242A1 (de) * 1989-02-21 1990-08-23 Basf Ag Verfahren zur herstellung von phenyloxdiazolylanilinen
NZ234760A (en) * 1989-08-18 1991-09-25 Sterling Drug Inc Antiviral oxazole compounds and compositions
DE4425794A1 (de) * 1994-07-21 1996-01-25 Basf Ag Nitrofarbstoffe
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
RU2003138074A (ru) 2001-06-08 2005-02-20 Цитови Инк. (US) Замещенные 3-арил-5-арил-[1,2,4]-оксадиазолы и их аналоги в качестве активаторов каспаз и индукторов апоптоза, а также их применение
MY151199A (en) 2001-11-02 2014-04-30 Rigel Pharmaceuticals Inc Substituted diphenyl heterocycles useful for treating hcv infection
NZ538339A (en) 2002-08-09 2007-01-26 Astrazeneca Ab Oxadiazoles as modulators of metabotropic glutamate receptor-5
GB0303503D0 (en) 2003-02-14 2003-03-19 Novartis Ag Organic compounds
EP3889142B1 (en) * 2003-04-11 2022-06-15 PTC Therapeutics, Inc. 1,2,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
US20050075375A1 (en) 2003-05-14 2005-04-07 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis C virus
CA2603402C (en) 2005-04-08 2017-10-31 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
MX2009002439A (es) * 2006-09-08 2009-03-27 Ptc Therapeutics Inc Procesos para la preparacion de acidos 1,2,4-oxadiazolbenzoicos.

Also Published As

Publication number Publication date
TWI482761B (zh) 2015-05-01
CA2842625C (en) 2016-07-12
US20100063297A1 (en) 2010-03-11
BRPI0716996B8 (pt) 2021-05-25
JP2014193896A (ja) 2014-10-09
PE20080771A1 (es) 2008-06-13
AR107474A2 (es) 2018-05-02
BRPI0716996B1 (pt) 2021-02-09
MX2009002439A (es) 2009-03-27
PT2059513E (pt) 2013-04-30
CN101535284B (zh) 2014-12-10
CA2842625A1 (en) 2008-03-13
US8367841B2 (en) 2013-02-05
DK2059513T3 (da) 2013-05-06
NZ598012A (en) 2013-08-30
BRPI0716996A2 (pt) 2013-10-08
AR062715A1 (es) 2008-11-26
IL197445A0 (en) 2009-12-24
NZ575511A (en) 2012-02-24
CN101535284A (zh) 2009-09-16
EP2059513B1 (en) 2013-01-23
MY148598A (en) 2013-05-15
PE20120669A1 (es) 2012-06-01
CA2662749C (en) 2015-01-20
HK1134094A1 (en) 2010-04-16
AR118922A2 (es) 2021-11-10
JP5955494B2 (ja) 2016-07-20
CA2662749A1 (en) 2008-03-13
ES2404348T3 (es) 2013-05-27
TW200823180A (en) 2008-06-01
AU2007292915A1 (en) 2008-03-13
AU2007292915B2 (en) 2012-07-26
RU2495030C2 (ru) 2013-10-10
KR101466368B1 (ko) 2014-11-27
US20080139818A1 (en) 2008-06-12
CL2007002606A1 (es) 2008-04-18
EP2059513A1 (en) 2009-05-20
IL197445A (en) 2014-01-30
ZA200901782B (en) 2010-06-30
KR20090054464A (ko) 2009-05-29
WO2008030570A1 (en) 2008-03-13
PL2059513T3 (pl) 2013-06-28
JP2010502715A (ja) 2010-01-28
US7678922B2 (en) 2010-03-16
RU2009113019A (ru) 2010-10-20

Similar Documents

Publication Publication Date Title
UA99265C2 (ru) Способ получения 1,2,4-оксадиазолбензойной кислоты и ее производных (варианты)
MX2009003909A (es) Métodos para dosificar un compuesto 1,2,4, - oxadiazol oralmente activo para el tratamiento de supresión de la mutación finalizadora.
EP2076501B8 (en) Crystalline forms of 3-[5-(2-fluorophenyl)-[1,2,4]oxadiazol-3-yl]-benzoic acid
NO20075682L (no) Sammensetninger omfattende et oralt aktivt 1,2,4-oksadiazol for nonsense mutasjonsundertrykkelsesterapi
HRP20130891T1 (en) DGAT inhibitor
NO2015002I1 (no) Ataluren (3-[5-(2-fluorfenyl)-[1,2,4]oksadiazol-3-yl]-benzosyre) og farmasøytisk akseptable salter og solvater derav
WO2007039122A3 (de) Feste, oral applizierbare pharmazeutische darreichungsformen mit schneller wirkstofffreisetzung
UA85693C2 (ru) Твердая фармацевтическая композиция для перорального применения, способ ее производства и ее применение
PL2947072T3 (pl) 1-(3-(6,7-dimetoksychinazolin-4-yloksy)fenylo)-3-(5-(1,1,1-trifluoro-2-metylopropan-2-ylo)izoksazol-3-ilo)mocznik jako modulator kinazy RAF w leczeniu chorób nowotworowych
IL187005A0 (en) Diacylglycerol acyltransferase inhibitors
TW200637558A (en) Solid, modified-release pharmaceutical dosage forms which can be administered orally
NZ593969A (en) Pyrazine derivatives useful as inhibitors of atr kinase
MX2009012285A (es) Inhibidores de diacilglicerol aciltransferasa.
NZ596154A (en) Cyclic compound having substituted phenyl group
MX2009005619A (es) Formas poliformicas del deferasirox (icl670a).
NZ597895A (en) Amide derivative
TW200833323A (en) Prophylactic or therapeutic agent for alopecia
MX2010004521A (es) Hidrato cristalino de agente betamimetico y su uso como medicamento.
CY1113938T1 (el) Διαδικασιες για την παρασκευη 1,2,4-οξαδιαζολο βενζοϊκων οξεων
WO2009024820A3 (en) Therapeutic treatment 014
SI2111401T1 (sl) 4-š4-Š(š3-terc.butil-1-Š3-(hidroksimetil)fenilĆ-1H-pirazol-5-ilćkarba- moil)-aminoĆ-3-fluorofenoksić-N-metilpiridin-2-karboksamid kot tudi njegova predzdravila in soli za zdavljenje raka